Evidence map›Paper›PMID 42173250›Full record

ArticleThe Journal of biological chemistry2026

A revised model for PHF20L1 Tudor function: DNA binding overrides methylation selectivity on nucleosomes.

Xiaolei Huang, Qin Xiao, Xin Liu, Xinci Shang, Zhuowen Wang, Haiyun Hu, Yinhao Zhou, Qiuyan Huang, Tao Jiang, Su Qin and 3 more

Abstract read
In one paragraph

Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Xiaolei HuangJiangsu Key Laboratory of Drug Discovery and Translational Research for Brain Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu, China; Jiangsu Province Engineering Research Center of Precision Diagnostics and Therapeutics Development, Soochow University, Suzhou, Jiangsu, China; College of Pharmaceutical Sciences, Suzhou International Joint Laboratory for Diagnosis and Treatment of Brain Diseases, Soochow University, Suzhou, Jiangsu, China. Electronic address: xlhuang@suda.edu.cn.
Qin XiaoJiangsu Key Laboratory of Drug Discovery and Translational Research for Brain Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu, China; Jiangsu Province Engineering Research Center of Precision Diagnostics and Therapeutics Development, Soochow University, Suzhou, Jiangsu, China; College of Pharmaceutical Sciences, Suzhou International Joint Laboratory for Diagnosis and Treatment of Brain Diseases, Soochow University, Suzhou, Jiangsu, China.
Xin LiuDivision of Life Sciences and Medicine, Department of Chemistry and the First Affiliated Hospital of USTC, School of Life Sciences and School of Biomedical Engineering, University of Science and Technology of China, Hefei, Anhui, China.
Xinci ShangJiangsu Key Laboratory of Drug Discovery and Translational Research for Brain Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu, China; Jiangsu Province Engineering Research Center of Precision Diagnostics and Therapeutics Development, Soochow University, Suzhou, Jiangsu, China; College of Pharmaceutical Sciences, Suzhou International Joint Laboratory for Diagnosis and Treatment of Brain Diseases, Soochow University, Suzhou, Jiangsu, China.
Zhuowen WangJiangsu Key Laboratory of Drug Discovery and Translational Research for Brain Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu, China; Jiangsu Province Engineering Research Center of Precision Diagnostics and Therapeutics Development, Soochow University, Suzhou, Jiangsu, China; College of Pharmaceutical Sciences, Suzhou International Joint Laboratory for Diagnosis and Treatment of Brain Diseases, Soochow University, Suzhou, Jiangsu, China.
Haiyun HuJiangsu Key Laboratory of Drug Discovery and Translational Research for Brain Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu, China; Jiangsu Province Engineering Research Center of Precision Diagnostics and Therapeutics Development, Soochow University, Suzhou, Jiangsu, China; College of Pharmaceutical Sciences, Suzhou International Joint Laboratory for Diagnosis and Treatment of Brain Diseases, Soochow University, Suzhou, Jiangsu, China.
Yinhao ZhouJiangsu Key Laboratory of Drug Discovery and Translational Research for Brain Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu, China; Jiangsu Province Engineering Research Center of Precision Diagnostics and Therapeutics Development, Soochow University, Suzhou, Jiangsu, China; College of Pharmaceutical Sciences, Suzhou International Joint Laboratory for Diagnosis and Treatment of Brain Diseases, Soochow University, Suzhou, Jiangsu, China.
Qiuyan HuangJiangsu Key Laboratory of Drug Discovery and Translational Research for Brain Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu, China; Jiangsu Province Engineering Research Center of Precision Diagnostics and Therapeutics Development, Soochow University, Suzhou, Jiangsu, China; College of Pharmaceutical Sciences, Suzhou International Joint Laboratory for Diagnosis and Treatment of Brain Diseases, Soochow University, Suzhou, Jiangsu, China.
Tao JiangJiangsu Key Laboratory of Drug Discovery and Translational Research for Brain Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu, China; Jiangsu Province Engineering Research Center of Precision Diagnostics and Therapeutics Development, Soochow University, Suzhou, Jiangsu, China; College of Pharmaceutical Sciences, Suzhou International Joint Laboratory for Diagnosis and Treatment of Brain Diseases, Soochow University, Suzhou, Jiangsu, China.
Su QinLife Science Research Center, Southern University of Science and Technology, Shenzhen, Guangdong, China.
Yangtong HuangJiangsu Key Laboratory of Drug Discovery and Translational Research for Brain Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu, China.
Jia-Bin LiJiangsu Key Laboratory of Drug Discovery and Translational Research for Brain Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu, China. Electronic address: lijiabin@suda.edu.cn.
Yanli LiuJiangsu Key Laboratory of Drug Discovery and Translational Research for Brain Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu, China; Jiangsu Province Engineering Research Center of Precision Diagnostics and Therapeutics Development, Soochow University, Suzhou, Jiangsu, China; College of Pharmaceutical Sciences, Suzhou International Joint Laboratory for Diagnosis and Treatment of Brain Diseases, Soochow University, Suzhou, Jiangsu, China. Electronic address: ylliu18@suda.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Plant homeodomain finger protein 20-like protein 1 (PHF20L1) is a methyl-lysine reader that regulates chromatin remodeling and transcription via its tandem Tudor and PHD finger domains. Here, we characterize the selectivity of these Tudor domains using biophysical and structural approaches. Quantitative fluorescence polarization (FP) and isothermal titration calorimetry (ITC) reveal that Tudor1 binds to both mono- and di-methylated H3K36 and H4K20, with a modest preference for H3K36me1, whereas Tudor2 is highly specific for H4K20me2. Their tandem arrangement enhances affinity for methylated H3K36 through cooperative binding. The crystal structure of Tudor1 in complex with H3K36me1 reveals the basis for its preference: a deep, narrow aromatic cage formed by Y24, Y29, F47, W50, and Y54 accommodates the mono-methylammonium group, while D23 contributes a critical hydrogen bond that stabilizes the interaction. Mutations in this cage abolish H3K36me1 binding, and mutation of corresponding cage-forming residues (W97A/Y103A, based on our solved apo Tudor2 structure) disrupts Tudor2 recognition of H4K20me2. Structural comparison across Tudor family readers for H3K36me and H4K20me further indicates that the number and orientation of acidic residues within the otherwise hydrophobic aromatic cages fine-tune selectivity among methyl-lysine states. Unexpectedly, nucleosome-binding assays reveal that the tandem Tudor domains bind to DNA with high affinity and lose methylation selectivity, contrasting sharply with the peptide-level results. Thus, our findings revise the mechanistic framework for PHF20L1 chromatin engagement: from a selective methyl-lysine reader to a high-affinity DNA-binding module on nucleosomes.

Indexed as

DNANuclear ProteinsNucleosomesBinding SitesHistonesMethylationModels, MolecularProtein BindingTudor DomainDNAHistonesNuclear ProteinsNucleosomeshistone bindingmethyl-lysinenucleosome binding PHF20L1Tudor domain

Identifiers

PMID42173250
PMCPMC13285377

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.